



- (51) **International Patent Classification:**
C12N 15/113 (2010.01) *A61P 27/02* (2006.01)
- (21) **International Application Number:**
PCT/EP2024/083282
- (22) **International Filing Date:**
22 November 2024 (22.11.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
23383191.6 22 November 2023 (22.11.2023) EP
- (71) **Applicant:** SYLENTIS S.A.U. [ES/ES]; Plaza del Descubridor Diego de Ordás no. 3, Planta 5, E-28003 Madrid (ES).
- (72) **Inventors:** JIMÉNEZ, Ana Isabel; c/o SYLENTIS, C/ Santiago Grisolia, nº2, Tres Cantos, 28760 Madrid (ES). MARTÍNEZ, Tamara; c/o SYLENTIS, C/ Santiago Grisolia, nº2, Tres Cantos, 28760 Madrid (ES). RAMOS, Facundo Nehuén; c/o SYLENTIS, C/ Santiago Grisolia, nº2, Tres Cantos, 28760 Madrid (ES).
- (74) **Agent:** MARKS & CLERK LLP; 15 Fetter Lane, London EC4A 1BW (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** SIRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF OCULAR RETINAL CONDITIONS

(57) **Abstract:** RNA interfering oligonucleotides targeting TSC1 are described for the treatment of retinal dystrophies. The RNAi oligonucleotides may be siRNAs, and may further comprise siRNAs targeting TSC2. Branched oligonucleotides comprising two or more siRNAs and product combinations of two or more different siRNAs are described, which in embodiments may target either or both of TSC1 and/or TSC2. The invention also relates to methods and compositions comprising such products.




FIG. 26

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*